Danflex 50 mg capsul Capsule

Danflex 50 mg capsul Capsule সম্পর্কে

Danflex 50 mg capsul Capsule একটি ক্যাপসুল ঔষধ, যার জেনেরিক নাম Dantrolene Sodium এবং শক্তি ৫০ mg। এটি তৈরি করে Opsonin Pharma Limited। Dantrolene Sodium-এর অন্য ব্র্যান্ডগুলো এই পাতায় কম দাম থেকে সাজানো আছে, দাম তুলনা করতে পারবেন। ডাক্তারের প্রেসক্রিপশন মেনে চলুন এবং অন্য ব্র্যান্ড খাওয়া যাবে কি না তা ফার্মাসিস্টের কাছ থেকে জেনে নিন।

Dantrolene Sodium-এর ৩টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত।

Danflex 50 mg capsul Capsule কী?

Danflex 50 mg capsul 50 mg capsule is a medicine made by Opsonin Pharma Limited. It acts on the muscle itself rather than at the nerve-muscle junction, helping to ease the tight, stiff muscles that can follow upper motor neuron problems such as spinal cord injury, stroke, cerebral palsy or multiple sclerosis. It is a prescription medicine, so the doctor decides whether it suits you, the dose and how long you take it, and checks your response over time.

Danflex 50 mg capsul-এর ব্যবহার

Only a doctor can confirm whether this medicine is appropriate for your condition and what course you need. It is not a general muscle pain remedy. Danflex 50 mg capsul is used to control the signs of chronic spasticity that come from upper motor neuron disorders, including spinal cord injury, stroke, cerebral palsy and multiple sclerosis.

Danflex 50 mg capsul কীভাবে ব্যবহার করবেন

Take Danflex 50 mg capsul exactly as your doctor prescribes, with the dose and schedule set for you alone. Danflex 50 mg capsul is taken by mouth. Swallow the capsule whole with water. Ask your doctor or pharmacist if you are unsure how to take it or what to do about a missed dose. Complete the course exactly as prescribed.

Danflex 50 mg capsul-এর পার্শ্বপ্রতিক্রিয়া

Drowsiness, dizziness, weakness, tiredness, general discomfort and diarrhoea are among the side effects reported with Dantrolene. Diarrhoea can sometimes be severe and may mean the medicine has to be paused or stopped. Tell your doctor about any side effect that bothers you or does not settle, and get medical help for severe diarrhoea. Contact your doctor if you notice anything unusual after taking it.

সতর্কতা ও নিরাপত্তা

In pregnancy it is used only if the benefit justifies the risk, and it should not be used while breastfeeding. Sunlight exposure can cause a skin reaction, so take care in the sun. Liver problems, including serious ones, can occur with Dantrolene, so the doctor will weigh the benefits and may stop treatment if no benefit is seen in good time. Keep out of reach of children.

সাধারণ প্রশ্ন

Why is Danflex 50 mg capsul prescribed?

Only a doctor can confirm whether this medicine is appropriate for your condition and what course you need. It is not a general muscle pain remedy.

How should I take Danflex 50 mg capsul?

Take Danflex 50 mg capsul exactly as your doctor prescribes, with the dose and schedule set for you alone. Danflex 50 mg capsul is taken by mouth.

What are the side effects of Danflex 50 mg capsul?

Drowsiness, dizziness, weakness, tiredness, general discomfort and diarrhoea are among the side effects reported with Dantrolene. Diarrhoea can sometimes be severe and may mean the medicine has to be paused or stopped.

Can I use Danflex 50 mg capsul in pregnancy or while breastfeeding?

In pregnancy it is used only if the benefit justifies the risk, and it should not be used while breastfeeding. Sunlight exposure can cause a skin reaction, so take care in the sun.

নির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

In Chronic Spasticity: Dantrolene is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuronal disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patients whose functional ... Read moreIn Chronic Spasticity: Dantrolene is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuronal disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patients whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrolene is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrolene therapy. In such instances, information regarding improvement should be solicited from the patient. Brief withdrawal of Dantrolene for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression.

A decision to continue the administration of Dantrolene on a long-term basis is justified if introduction of the drug into the patient's regimen:
  • produces a significant reduction in painful and/or disabling spasticity such as clonus, or
  • permits a significant reduction in the intensity and/or degree of nursing care required, or
  • rids the patient of any annoying manifestation of spasticity considered important by the patient himself.
In Malignant Hyperthermia: Oral Dantrolene is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery. Oral Dantrolene should be administered following a malignant hyperthermic crisis to prevent recurrence of the signs of malignant hyperthermia.

ফার্মাকোলজি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Dantrolene produces relaxation by affecting the contractile response of the skeletal muscle at a site beyond the myoneural junction, directly on the muscle itself. In skeletal muscle, Dantrolene dissociates the excitation-contraction coupling, probably by interfering with the release of Ca++ from the sarcoplasmic reticulum.

মাত্রা ও সেবনবিধি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

For Use in Chronic Spasticity:
  • Adults: The following gradual titration schedule is suggested. Some patients will not respond until higher daily dosage is achieved. Each dosage level should be maintained for seven days to determine the patient's response. If no further benefit is observed at the next higher dose, dosage should be decreased to the previous lower dose.
  • Starting dose is 25 mg twice per day and it can be increased to 25-50 mg per day per week. Maximum accepted dosage is 400 mg per day.
  • Paediatric Patients: The following gradual titration schedule is suggested. Some patients will not respond until higher daily dosage is achieved. Each dosage level should be maintained for seven days to determine the patient's response. If no further benefit is observed at the next higher dose, dosage should be decreased to the previous lower dose.
  • 0.5 mg/kg once daily for seven days, then 0.5 mg/kg 3 times for 7 days, 1 mg/kg 3 times for 7 days, 2 mg/kg 3 times a day, Therapy with a dose 4 times daily may be necessary for some individuals.
For Malignant Hyperthermia
  • Preoperatively: Administer 4 to 8 mg/kg/day of oral Dantrolene in 3 or 4 divided doses for one or two days prior to surgery, with the last dose being given approximately 3 to 4 hours before scheduled surgery with a minimum of water.
  • Post Crisis Follow-up: Oral Dantrolene should also be administered following a malignant hyperthermia crisis, in doses of 4 to 8 mg/kg per day in four divided doses, for a one to three day period to prevent recurrence of the manifestations of malignant hyperthermia.

ঔষধের মিথষ্ক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Drowsiness may occur with Dantrolene therapy, and the concomitant administration of CNS depressants such as sedatives and tranquilizing agents may result in further drowsiness. Hepatotoxicity has occurred more often in women over 35 years of age receiving concomitant estrogen therapy.

প্রতিনির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Active hepatic disease, such as hepatitis and cirrhosis.

পার্শ্ব প্রতিক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

The most frequently occurring side effects of Dantrolene have been drowsiness, dizziness, weakness, general malaise, fatigue, and diarrhea. These are generally transient, occurring early in treatment, and can often be obviated by beginning with a low dose and increasing dosage gradually until an optimal regimen is established. Diarrhea may be severe and may necessitate temporary withdrawal of Dantrolene therapy. If diarrhea recurs upon readministration of Dantrolene, therapy should probably be withdrawn permanently

গর্ভাবস্থায় ও স্তন্যদানকালে

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Pregnancy Category C. Dantrolene capsules should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Dantrolene should not be used in nursing mothers.

সতর্কতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

In view of the potential for liver damage in long-term Dantrolene use, therapy should be stopped if benefits are not evident within 45 days. Patients should be cautioned against driving a motor vehicle or participating in hazardous occupations while taking Dantrolene. Caution should be exercised in the concomitant administration of tranquilizing agents. Dantrolene might possibly evoke a photosensitivity reaction; patients should be cautioned about exposure to sunlight while taking it. It is important to recognize that fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with Dantrolene therapy. At the start of Dantrolene therapy, it is desirable to do liver function studies (SGOT, SGPT, alkaline phosphatase, total bilirubin) for a baseline or to establish whether there is preexisting liver disease. Liver function studies (e.g., SGOT or SGPT) should be performed at appropriate intervals during Dantrolene therapy. Some patients have revealed a return to normal laboratory values in the face of continued therapy while others have not. If symptoms compatible with hepatitis, accompanied by abnormalities in liver function tests or jaundice appear, Dantrolene should be discontinued. If caused by Dantrolene and detected early, the abnormalities in liver function characteristically have reverted to normal when the drug was discontinued. Dantrolene therapy has been reinstituted in a few patients who have developed clinical and/ or laboratory evidence of hepatocellular injury. If such reinstitution of therapy is done, it should be attempted only in patients who clearly need Dantrolene and only after previous symptoms and laboratory abnormalities have cleared. The patient should be hospitalized and the drug should be restarted in very small and gradually increasing doses. Laboratory monitoring should be frequent and the drug should be withdrawn immediately if there is any indication of recurrent liver involvement. Dantrolene should be used with particular caution in females and in patients over 35 years of age in view of apparent greater likelihood of drug-induced, potentially fatal, hepatocellular disease in these groups.

Dantrolene should be used with caution in patients with impaired pulmonary function, and in patients with severely impaired cardiac function due to myocardial disease. It should be used with caution in patients with a history of previous liver disease or dysfunction.

সংরক্ষণ

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Store in a cool & dry place, protected from light.

বিকল্প ব্র্যান্ড: Dantrolene Sodium

একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।

ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।